Urticarial hypersensitivity reaction caused by temozolomide

Journal of Drugs in Dermatology

Volumn 9, Issue 9, 2010, Pages 1142-1144

  Pothiawala, Salma ^a   Hsu, Mei Yu ^b   Yang, F Clarissa ^b   Kesari, Santosh ^c   Ibrahimi, Omar A ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINONIDE; PREDNISONE; STEROID; TEMOZOLOMIDE; ALKYLATING AGENT; ANTIINFLAMMATORY AGENT; DACARBAZINE; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; ANAPLASTIC OLIGOASTROCYTOMA; ARTICLE; ASTROCYTOMA; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHRONIC URTICARIA; EOSINOPHILIA; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRURITUS; RASH; SKIN DEFECT; URTICARIA; URTICARIAL HYPERSENSITIVITY REACTION; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; EOSINOPHIL; PATHOLOGY; SKIN;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; DACARBAZINE; DRUG ERUPTIONS; EOSINOPHILS; FLUOCINONIDE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; SKIN; URTICARIA;

EID: 77957933172     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Chua SL, Rosenthal MA, Wong SS, et al. Phase 2 study of TMZ and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol. 2004;6(1):38-43. (Pubitemid 38139638)
2. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf. 2009;8(4):493-499.
3. Horton TM, Thompson PA, Berg SL, et al.; Children's Oncology Group Study. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: A Children's Oncology Group Study. J Clin Oncol. 2007;25(31):4922-4928 (Pubitemid 350220423)
4. Pick AM, Neff WJ, Nystrom KK. TMZ-induced desquamative skin rash in a patient with metastatic melanoma. Pharmacotherapy. 2008;28(3):406-409. (Pubitemid 351328913)
5. Kubicek GJ, Werner-Wasik M, Machtay M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent TMZ and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2009;74(2):433-499.
6. Trudeau ME, Crump M, Charpentier D, et al. TMZ in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006;17(6):952-956. (Pubitemid 43778985)
7. Sarma N. Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. Am J Clin Dermatol. 2009;10(4):264-267.
8. Krown SE, Niedzwiecki D, Hwu WJ, et al.; Cancer and Leukemia Group B. Phase II study of TMZ and thalidomide in patients with metastatic melanoma in the brain: High rate of thromboembolic events (CALGB 500102). Cancer. 2006;107(8):1883-1890. (Pubitemid 44582959)
9. Bael TE, Peterson BL, Gollob JA. Phase II trial of arsenic trioxide and ascorbic acid with TMZ in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res. 2008;18(2):147-151. (Pubitemid 351398270)